09:00 AM EDT, 05/29/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday that topline results from a phase 3 trial evaluating seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder met all primary and secondary endpoints.

The company said seltorexant demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms, as well as improved sleep disturbance outcomes.

The findings will be presented at the American Society of Clinical Psychopharmacology annual meeting, which is being held this week in Miami, Florida.

Price: 144.25, Change: -0.13, Percent Change: -0.09